Poor Indoor Air Quality Exposure and Clinical Risks with Edward Brooks, MD, and Charlene McEvoy, MD

Published on: 

Strategic Alliance Partnership | <b>American Lung Association</b>

The pair of pulmonology and microbiology experts join the podcast to discuss what clinicians should look out for in indoor pollutant exposure risks, and how to manage their impact.

An unforeseen consequence of isolation and quarantine in response to reduce COVID-19 exposure risk has been the increased exposure to indoor air pollutants and poor indoor environments.

In fact, as allergists have explained to HCPLive, many patients have commonly misinterpreted emerging allergy exposure symptoms as COVID-19 symptoms. It’s an entirely different risk for clinicians to identify and help provide care for.

In the latest episode of Lungcast, a pair of experts join American Lung Association (ALA) chief medical officer Albert Rizzo, MD, to discuss how these risks manifest and how they can be mitigated by patients and clinicians alike.

Edward G. Brooks, a professor in Microbiology, Immunology & Molecular Genetics at the University of Texas San Antonio and Charlene McEvoy, MD, a pulmonologist and assistant professor of Medicine at the University of Minnesota, headline the comprehensive discussion into indoor air quality health.

Rizzo, Brooks, and McEvo also review the recent recall of benzene exposure-risk products in the dry shampoo industry, as well as navigating issues without other carcinogens including radon exposure.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms: